A note from BlueGene Precision Partners
This week’s signal is clear: progress in rare disease and neurology depends on more than promising science. It depends on teams that can translate complex biology into disciplined development, meaningful patient partnership, and credible execution.
For founders, that means being intentional about the leaders you bring in before the next financing, data readout, or regulatory milestone. For people considering a move, it means looking beyond a title: find the mission, decision rights, and patient connection that let you do your best work.
At BlueGene Precision Partners, we continue to connect purpose-led rare disease, neuro, biotech, and medtech organizations with leaders who can build through uncertainty—and keep patients at the center. If you are planning a key leadership hire, building a patient-informed team, or exploring your next chapter, I would welcome the conversation.
Industry pulse: capital is still choosing conviction
Vaderis Therapeutics raised a $152 million Series B to advance its AKT inhibitor through Phase 3 for a rare blood-vessel disorder. The round is a reminder that differentiated assets with a defined regulatory path and a clear patient need can still command substantial capital. Read the funding update
In the first half of 2026, FDA approved six orphan drugs, including Rocket Pharmaceuticals’ Kresladi for leukocyte adhesion deficiency-I and Regeneron’s Otarmeni for a genetic form of hearing loss. The pace also underscores the importance of strong regulatory, market-access, and patient-services talent well before launch. Read BioSpace’s review
Two late-August regulatory moments to watch: Capricor’s deramiocel for Duchenne muscular dystrophy (August 22) and Ultragenyx’s DTX401 for glycogen storage disease type 1a (August 23). See the 2026 orphan-drug calendar
What this means for founders: Do not wait for a pivotal event to define your launch or scale-up bench. The strongest organizations are mapping clinical, regulatory, commercial, access, and patient-advocacy leadership in parallel—not in sequence.
MS & neuro watch
New MS research reported by the Multiple Sclerosis Association of America highlighted that fenebrutinib reduced relapses and MRI evidence of disease activity versus teriflunomide in two studies involving nearly 1,500 people with relapsing MS. The same update noted durable disease-activity reductions reported with frexalimab and quality-of-life findings from a Phase IV Kesimpta study. Read the MSAA research update
UCLA received $7.49 million to advance an off-the-shelf CAR-NKT cell therapy for MS toward its first human trial. The program is designed to target B cells and inflammation—an early but important example of cell-therapy thinking entering the MS landscape. Read the UCLA program update
Patient and advocacy lens: As modalities grow more complex, patient-facing clarity must grow with them. Trial design, consent, burden of participation, access planning, and community communication should be treated as development work—not downstream communications work.
Leaders and companies to watch
Claus Sundgreen, M.D. joined NRG Therapeutics as Chief Medical Officer, effective August 1. NRG is a clinical-stage neuroscience company developing disease-modifying therapies aimed at mitochondrial dysfunction in neurodegenerative disease. This is a useful signal for candidates with clinical-development and translational-neuroscience experience. Read the appointment
Herantis Pharma appointed Juha Savola, M.D., Ph.D. as Chief Medical Officer in June. His experience spans neurology, gene therapy, and rare disease, and Herantis is focused on disease-modifying approaches for Parkinson’s disease. Read the appointment
Galibra Neuroscience received FDA Orphan Drug and Rare Pediatric Disease designations for a gene-therapy program in SSADH deficiency. It is an early-stage company to put on the radar for genetic neurodevelopmental disease and gene-therapy talent. Read the update
The talent angle
The highest-demand profiles I am seeing across rare disease and neuro are not simply functional experts. They are connectors—leaders who can align science, operations, advocacy, and capital around a shared development story.
For candidates, three questions worth asking in every conversation:
What evidence will define success in the next 12–18 months, and who owns it?
How are patients and advocates influencing program decisions today?
What must this role build—not merely operate—to make the next milestone possible?
For hiring leaders: assess for cross-functional trust and patient fluency alongside technical depth. Those capabilities are increasingly central to execution.
Advocacy watch
The Global Genes 2026 RARE Drug Development Symposium takes place September 9–11 in Boston. The gathering is positioned around connecting stakeholders to advance rare disease drug development—an opportunity for founders, advocates, and talent leaders to compare notes on the practical barriers between a promising program and an accessible therapy.
Will you be in Boston? If you are attending—or are considering it—reply to this newsletter or send me a message. I would love to coordinate a coffee, make a thoughtful introduction, or compare notes on the talent and patient-partnership capabilities that will move rare disease programs forward.
What I’m grateful for
I am grateful for the people who continue to bring rigor and humanity to difficult work: patients and care partners who share their lived experience, advocates who keep urgency visible, and leaders who build teams worthy of the science.
If someone in your network is quietly doing this work well, send them a note this week. Recognition is a small act—but in this field, it can carry real weight.
Let’s connect
Are you building a rare disease, neuro, biotech, or medtech team—or considering what your next role should make possible? Reply to this newsletter or message me. I am always glad to connect thoughtful people doing meaningful work.
Corners & Connect is a weekly note from BlueGene Precision Partners on rare disease, neuro, patient-centered innovation, and the talent that moves it forward.
